Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study To Evaluate The Efficacy And Safety Of PF-00547659 In Subjects With Crohn's Disease (OPERA)

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study To Evaluate The Efficacy And Safety Of PF-00547659 In Subjects With Crohn's Disease (OPERA)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ontamalimab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms OPERA
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Jul 2022 Results reporting long-term safety and efficacy data for over 72 weeks published in the Inflammatory Bowel Diseases
    • 02 Mar 2020 Patients (n=440) were included from this and NCT01276509 studies in the PK and pharmacodynamic analyses based on the PK population of the trials published in the Journal of Clinical Pharmacology
    • 24 Oct 2018 Results from NCT01276509, NCT01620255 assessing efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of SHP647 in patients with ulcerative colitis or crohn's disease, presented at the 26th United European Gastroenterology Week.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top